PharmaVoice

NOVEMBER 28, 2022

Psychedelic drug trials pose a number of challenges, but researchers can take these steps to boost patient safety.

100

100

The Spirit Pharmacist

AUGUST 13, 2023

Diabetes has largely been exclusionary criteria from clinical trials, yet are all persons with diabetes truly high risk candidates to use psychedelics? Should medications generally be continued or stopped to use psychedelics? If persons are using anti-diabetic medications, is there anything special to consider or worry about?

98

98

Pharmacy Times

JANUARY 13, 2023

Jordan Sloshower, MD, MSc, explains his experience working in several clinical trials investigating psilocybin-assisted therapy.

139

139

European Pharmaceutical Review

APRIL 13, 2023

Psychedelics are a class of psychoactive substances that produce temporary changes in perception, mood and cognitive processes. 1 Some psychedelics are found in nature, including psilocybin, a naturally occurring molecule found in almost 150 species of mushrooms which turns into psilocin once ingested, causing psychedelic effects.

Pharmaceutical Companies 114

Pharmaceutical Companies Pharmaceutical Companies FDA 114

STAT

JULY 3, 2023

DENVER — The founder of Field Trip , a chain of shuttered ketamine clinics currently facing insolvency, put forward an unexpected theory of how psychedelics work to treat depression last month. Read the rest…

101

101

Pharmacy Times

MAY 19, 2023

Rick Strassman, MD, a clinical researcher, author, and expert in psychedelic medicines, sat down to discuss pharmacists' role in adverse event management.

123

123

pharmaphorum

JANUARY 5, 2024

Beckley Psytech has announced that is has received substantial strategic investment from atai Life Sciences, totalling $50 million, to accelerate the clinical development of short-duration psychedelics.

88

88

STAT

MAY 16, 2023

A chain of luxury ketamine clinics called Field Trip started churning through business strategies at an increasingly rapid pace late last year. The money was running out, clinics were half full, and the company’s vice president of clinical services was under intense pressure to launch an at-home ketamine service.

95

95

Pharmafile

APRIL 25, 2023

read more

40

40

Outsourcing Pharma

OCTOBER 20, 2023

Feedback has been submitted to the US Food and Drug Administration (FDA) with guidelines intended for sponsors of clinical trials related to psychedelic compounds.

FDA 93

FDA Compounding 93

European Pharmaceutical Review

DECEMBER 21, 2022

Psychedelic research, in particular, is gaining momentum. . Regardless, most psychedelic drugs are Schedule I controlled substances, which means that very strict legal and regulatory controls accompany their use. Up until recently, it took a prohibitive stance toward psychedelic research.

Compounding 107

Compounding Controlled Substances FDA Patient Care 107

European Pharmaceutical Review

JUNE 28, 2023

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved a first-of-its-kind trial to run this year to test psychedelic drugs as a treatment for major depressive disorder (MDD). The clinical trial will combine dosages of a new psilocin-based drug with specialist therapy.

Dosage 74

Dosage FDA 74

Outsourcing Pharma

NOVEMBER 10, 2023

A partnership between clinical research technology company uMotif and cognitive science company, Cogstate Limited, will see the companies continue existing work that includes a major phase 2 clinical trial of a psychedelic therapeutic.

70

70

Outsourcing Pharma

AUGUST 3, 2021

The Psychae Institute, established by a global team of scientists, will conduct pre-clinical and clinical research around psychedelic medicine development.

130

130

The Spirit Pharmacist

OCTOBER 1, 2022

This vlog features a sneak peek at a content module from one of my courses titled ' Breakthrough Psychedelics: MDMA, Psilocybin, and Ketamine ' and is a summary discussion that compares and contrasts the pharmacology and clinical characteristics of MDMA, psilocybin, and ketamine. This is why put together the online course.

96

96

STAT

MAY 30, 2023

It is defined as dedicating oneself to a life free of drugs and alcohol — except for cannabis and other psychedelics. Though many consumers don’t think of cannabis as a psychedelic, policy experts often consider it one because of its effects.)

98

98

pharmaphorum

MARCH 2, 2022

There is a growing pipeline of psychedelic therapies and an expanding body of science to suggest that they may be able to provide an alternative to existing mental health treatments. The image of psychedelic drugs within medical research is changing. A psychedelic renaissance.

Compounding 102

Compounding FDA 102

STAT

NOVEMBER 7, 2023

doctors scale back their use of  opioid painkillers , a new option for hard-to-treat pain is taking root: ketamine, the decades-old surgical drug that is now a  trendy psychedelic therapy. WASHINGTON (AP) — As U.S.

95

95

The Spirit Pharmacist

NOVEMBER 29, 2022

Choosing a Psychedelic Retreat. Attending a psychedelic retreat can be a great way to experience and benefit from psychedelics. The opportunity to travel, change scenery, take time and space for yourself, and experience psychedelics in controlled or ritualistic environments can create powerful effects.

102

102

European Pharmaceutical Review

DECEMBER 13, 2022

North American psychedelic drug developers Mindset, PharmAla, Mydecine and Psyence have signed with clinical research organisation (CRO) Clerkenwell Health to trial therapies for mental health conditions, in London, UK, to benefit from the country’s swift drug regulatory process.

Compounding 99

Compounding FDA 99

pharmaphorum

AUGUST 16, 2021

UK psychedelic medicine specialist Beckley Psytech has raised an impressive £58 million (around $80 million) in an oversubscribed second-round financing that will help fund clinical development of its psilocybin-based therapies. Beckley – formerly known as Beckley Canopy Therapeutics – raised £7.4

Compounding 135

Compounding 135

Outsourcing Pharma

JULY 4, 2023

Clerkenwell Health, a specialist clinical research organisation (CRO) focused on supporting clients with the design and delivery of psychedelic-assisted therapy trials, is sponsoring the upcoming Psych Symposium 2023 on Thursday 6 July in London.

67

67

Pharmafile

FEBRUARY 22, 2023

Beckley Psytech, a private, clinical-stage biotech company, announced that the FDA has granted Investigational New Drug (IND) approval for their global multi-site phase 2b study into psychedelic drug BPL-003. BPL-003 is indicated for use in patients with Treatment Resistant Depression (TRD). read more

FDA 59

FDA Compounding 59

pharmaphorum

OCTOBER 2, 2020

Psychedelic therapy company Field Trip Psychedelics has announced that it will soon join the growing list of psychedelic companies going public. . COMP360 is a crystalline formulation of psilocybin in phase 2b clinical development in patients who have not responded to standard therapy for depression. per Class A share. .

Compounding 118

Compounding FDA 118

Fierce Healthcare

JUNE 28, 2023

assets of Field Trip Health, a psychedelic therapy provider. | The company will assume operations of Field Trip clinics in New York and Washington, D.C., Stella, a behavioral health provider specializing in PTSD treatment, has acquired the U.S. and plans to open a new treatment center in Southern California.

70

70

pharmaphorum

SEPTEMBER 14, 2021

The first patient has received a low dose of Beckley Psytech’s psychedelic medicine psilocybin in a clinical trial for short-lasting unilateral neuralgiform headache attacks (SUNHA), a rare disorder. The UK company says that SUNHA is a debilitating condition that is estimated to affect 40,000 patients in US and Europe.

Compounding 104

Compounding Labelling 104

Psychadelic Pharmacist

DECEMBER 21, 2021

In the first installment of the Psychedelic Pharmacist Interview Series, Dr. Kelan Thomas speaks with Psychedelic Pharmacists Association co-founder Dr. Michael Haichin about his unique career path, the future of psychedelics in pharmacy, and more. See below for additional show notes.

52

52

Pharma Times

JANUARY 24, 2022

Beckley Psytech leads a new project focused on addressing psychiatric and neurological conditions through the use of psychedelic medicines.

42

42

pharmaphorum

DECEMBER 17, 2020

In the last few years, biopharma companies focusing on psychedelic medicines have been springing up like mushrooms – magic or otherwise – and venture capital money is starting to follow. In September, Compass became the first psychedelic medicine company to float on the Nasdaq, raising $127 million , and is now trading at a market cap of $1.98

87

87

pharmaphorum

FEBRUARY 19, 2021

Psychedelic medicine biotech MindMed is to acquire digital medicine and therapeutics startup HealthMode for around $32.2 With the acquisition MindMed gains access to HealthMode’s intellectual property, platforms for clinical drug trials, and its entire 24-strong digital medicine team.

FDA 116

FDA 116

pharmaphorum

SEPTEMBER 21, 2020

Compass Pathways and its potential magic mushroom depression drug went public last week – and now psychedelic therapy firm Mind Medicine is aiming to follow suit by up-listing its shares on the Nasdaq. UK-based Compass has a patented synthetic version of psilocybin, the active ingredient in magic mushrooms, and raised around $127.5

Compounding 134

Compounding FDA 134

pharmaphorum

NOVEMBER 3, 2021

Psychedelic medicines specialist Beckley Psytech has enticed a senior figure in Janssen’s neuroscience division to take on the role of its chief medical officer as it ushers its first drugs through clinical trials. The post Psychedelics startup Beckley attracts Janssen neuroscience VP appeared first on. Dr Frank Wiegand.

59

59

The Spirit Pharmacist

MAY 23, 2023

Persisting Perceptual Phenomenon after Psychedelics Psychedelic drug intoxication is hallmarked by changes to our sensory experience and hallucinatory type activity. In most cases, effects of psychedelics are transient and end as concentrations of drug in the body fall. However, this is not true in all cases of use.

Compounding 52

Compounding 52

The Spirit Pharmacist

NOVEMBER 8, 2022

How often should I use psychedelics? It's both a good and commonly asked question so I decided to put together this video blog and accompanying text to help persons understand more of what my thought process is when approaching this question and share some insights depending on the method or indication for psychedelic use. Microdosing.

52

52

pharmaphorum

MAY 7, 2021

Small Pharma is following the trend for development of psychedelic medicines, a field where research has been suppressed for years because of legal restrictions on use of these compounds in many countries. The goal of the trial is for proof of concept of the drug as a wrap-around therapy for Major Depressive Disorder.

Compounding 92

Compounding 92

The Spirit Pharmacist

DECEMBER 7, 2021

7 Questions about Psychedelics and the Pharmacist. Friends, pharmacists, and media often ask me questions about psychedelics and pharmacy or psychedelic and the role of the pharmacist. Take a look below or watch the video above to get my thoughts on these important questions relating to psychedelics and pharmacist.

Medical Records 52

Medical Records Documentation Insurance 52

The Spirit Pharmacist

NOVEMBER 6, 2021

Antidepressant and Psychedelic Interactions. The most common situations and clinical scenarios I consult about have to do with persons taking antidepressants that are interested in psychedelic therapies or have tried them while taking antidepressants with lackluster results. Antidepressant and Psychedelic Drug Interaction Chart.

52

52